In a report released on October 7, Marc Goodman from Leerink Partners maintained a Buy rating on Axsome Therapeutics. The company’s shares closed yesterday at $122.52.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Goodman is a 5-star analyst with an average return of 13.7% and a 54.36% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Alkermes, ACADIA Pharmaceuticals, and Jazz Pharmaceuticals.
Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $171.42.
The company has a one-year high of $139.13 and a one-year low of $75.56. Currently, Axsome Therapeutics has an average volume of 573.9K.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AXSM in relation to earlier this year. Last month, Mark Coleman, a Director at AXSM bought 1,575.00 shares for a total of $200,466.30.
Read More on AXSM:
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)
